Proteomic analysis of dunning prostate cancer cell lines with variable metastatic potential using SELDI-TOF

被引:30
作者
Gretzer, MB
Chan, DW
van Rootselaar, CL
Rosenzweig, JM
Dalrymple, S
Mangold, LA
Partin, AW
Veltri, RW
机构
[1] Johns Hopkins Univ Hosp, James Buchanan Brady Urol Inst, Baltimore, MD 21287 USA
[2] Johns Hopkins Univ Hosp, Dept Pathol, Baltimore, MD 21287 USA
关键词
proteomics; SELDI-TOF; prostate cancer; progression; metastasis; Dunning rat tumor cell lines;
D O I
10.1002/pros.20066
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND. Surface enhanced laser desorption and ionization-time-of-flight (SELDI-TOF) is an evolving proteomic technology for improving biomarker discovery that allows for rapid and sensitive analysis of complex protein mixtures generated from body fluids, cells, and/or tissues. SELDI-based profiling identifies unique, differentially expressed proteins relating to specific cancer-related disease states. We utilized SELDI-TOF following preprocessing with molecular separation and chemical fractionation of cell membrane extracts from three Dunning rat prostate cancer cell lines of varying metastatic potential to search novel proteins that are differentially expressed. METHODS. Dunning rat cell sublines of variable (%) metastatic potential; G (0%), AT-1 (20%), and Mat-Ly-Lu (100%) were cultured in two different laboratories. Cell lysis was performed in a homogenation buffer (320 mM sucrose/50 mM Tris/0.5 mM PSMF) using Dounce homogenation. After centrifugation, the membrane pellet was washed 2x and then solublized in 2% CHAPS/8 M urea. This sample was further processed using positive pressure molecular ultrafiltration at 30 kDa or precipitation with 50% ammonium sulfate. Next, each sample was applied to an IMAC3-Ni ProteinChip (Ciphergen Biosystems, Freemont, CA) and analyzed using Ciphergen's Protein Biology System with protein peak analysis software. RESULTS. SELDI-TOF analysis differentiated the three Dunning rat cell sublines based upon protein concentration normalized profiles between 5,000 and 20,000 Da. The preparations from the three cells lines showed clear differences when the extracts from the metastatic sublines (AT-1 and MLL) were compared to the benign subline (G) for proteins with molecular weights of 9 kDa (decrease), 12 kDa (significant decrease), 14 kDa (decrease), and 17 kDa (significant gain). After pre-processing extracts with ammonium sulfate and molecular ultrafiltration, the molecular profile changes from one subline to the next became more apparent. Our results were reproducible using multiple runs including from Dunning cells cultured in a separate laboratory, and using different lots of SELDI ProteinChips. CONCLUSIONS. The application of SELDI-TOF to a series of Dunning rat prostate cancer cell lines illustrated apparent changes in protein profiles among the three cell lines with known differences in metastatic biologic activity. SELDI-TOF identified four reproducible changes in protein expression in the ATI and MLL metastatic cell sublines. Three of the expression changes were manifested as decreases, but one protein (17 kDa) was over-expressed in the AT1 and MLL cell lines. Emphasis will be placed on the isolation, purification, and characterization of the 17 kDa over-expressed protein and its potential role in PCa metastasis. (C) 2004 Wiley-Liss, Inc.
引用
收藏
页码:325 / 331
页数:7
相关论文
共 39 条
[1]  
Adam Bao-Ling, 2001, Proceedings of the American Association for Cancer Research Annual Meeting, V42, P142
[2]  
Adam BL, 2001, PROTEOMICS, V1, P1264, DOI 10.1002/1615-9861(200110)1:10<1264::AID-PROT1264>3.0.CO
[3]  
2-R
[4]  
ADAM BL, 2002, P AM ASSOC CANC RES, V41, P564
[5]   Proteomics: applications in basic and applied biology [J].
Anderson, NL ;
Matheson, AD ;
Steiner, S .
CURRENT OPINION IN BIOTECHNOLOGY, 2000, 11 (04) :408-412
[6]   Proteomics: new perspectives, new biomedical opportunities [J].
Banks, RE ;
Dunn, MJ ;
Hochstrasser, DF ;
Sanchez, JC ;
Blackstock, W ;
Pappin, DJ ;
Selby, PJ .
LANCET, 2000, 356 (9243) :1749-1756
[7]   Use of animal models in defining efficacy of chemoprevention agents against prostate cancer [J].
Bosland, MC .
EUROPEAN UROLOGY, 1999, 35 (5-6) :459-463
[8]   A GUIDE TO THE INTERPRETATION OF SERUM PROSTATE-SPECIFIC ANTIGEN LEVELS [J].
BUNTING, PS .
CLINICAL BIOCHEMISTRY, 1995, 28 (03) :221-241
[9]  
CARTER HB, 1988, J UROLOGY, V140, P173
[10]  
Carter HB., 2002, CAMPBELLS UROLOGY, VEighth, P3055